US Corporate Distress Financial Stress SEC Filings — August 31, 2026

Received NYSE American delisting notice on Aug 21, 2026; auditor resignation (LAO Professionals, June 8) and new appointment (TQ International, Aug 26) create governance overhang. No insider buying or forward guidance—management appears passive.

Nasdaq delisting finalized on Aug 25, 2026; trading suspended since Mar 27, 2026 (5+ months). Shares moving to OTC Expert Market—liquidity will collapse. No insider transactions or capital allocation actions reported.

Nasdaq bid price deficiency notice on Aug 26, 2026; 180-day cure period ends Feb 2027. Stock trading at ~$0.85 (below $1 threshold). No insider buying or forward guidance—risk of delisting if no reverse split or price recovery.

Resolved Nasdaq deficiency (public float <500k shares) after 1-for-4 reverse split; compliance demonstrated Aug 21, 2026. Mixed sentiment suggests temporary relief but no growth catalyst. [NEUTRAL/BEARISH]

Three delisting events in one week (Aug 21-26, 2026) across different sectors—potential systemic liquidity stress in micro-cap space. No insider buying in any filing.

Northann Corp.'s auditor change (LAO Professionals resigned June 8, TQ International appointed Aug 26) is a classic distress signal—often precedes accounting restatements or fraud revelations.

Zero forward-looking statements across all four filings—companies are not providing revenue/margin targets, indicating extreme uncertainty.

No dividends, buybacks, or M&A activity reported in any filing—cash conservation mode across the board.

NYSE American delisting appeal pending; auditor resignation (LAO Professionals) on June 8, 2026, and new auditor (TQ International) appointed Aug 26—audit gaps create restatement risk.

Nasdaq Listing Council affirmed delisting on Aug 25, 2026; trading suspended since Mar 27, 2026. Shares moving to OTC Expert Market—zero institutional coverage likely.

Average closing bid price below $1.00 for 30 consecutive days as of Aug 26, 2026. 180-day cure period ends Feb 2027; failure to regain compliance leads to delisting. No insider buying to signal confidence.

1-for-4 reverse split on Aug 14, 2026, triggered public float deficiency. Resolved but signals equity dilution and low stock price—potential for further splits.

Three micro-cap delisting events in one week (Aug 21-26) may trigger forced selling by index funds and margin calls across the sector.

Across all four filings, zero insider purchases reported—management teams are not backing their own stock with personal capital.

All four filings lack any revenue, EBITDA, or cash flow guidance—companies are operating in the dark.

No dividends, buybacks, or debt repayments reported—cash burn without shareholder returns.

180-day window (to Feb 2027) for potential reverse split or operational turnaround. If battery demand improves, stock could recover above $1. Monitor Q3 2026 earnings for revenue growth.

Oral hearing requested Aug 28, 2026—if successful, shares could relist. NYSE American hearings often result in extended compliance plans.

Nasdaq closed review with no further action—stock remains listed. If company delivers positive earnings surprise, could re-rate from distressed levels.

Shares moving to OTC Expert Market may create pricing inefficiencies. If company resolves filing issues and relists, early buyers could benefit.

Microvast (MVST) has high short interest (~15% of float). Any positive news (e.g., contract win, reverse split approval) could trigger a squeeze.

None of these companies have public debt, but if any issue convertible notes at distressed prices, could offer high-yield opportunity.

If Fed pivots to rate cuts in H2 2026, micro-cap liquidity could improve, benefiting these distressed names.

Three of four filings involve delisting threats (Northann, Cambium, Microvast) within one week—signaling a systemic liquidity crisis in sub-$100M market cap companies. No sector diversification (industrials, telecom, battery tech) suggests broad-based distress.

Northann Corp.'s auditor resignation (LAO Professionals) on June 8, 2026, preceded delisting notice by 2.5 months—audit quality issues are a reliable distress signal.

Profusa's 1-for-4 reverse split triggered a new deficiency (public float <500k shares)—reverse splits often fail to cure underlying business issues and create new compliance problems.

No insider purchases reported in any of the four filings—management teams are not signaling confidence with personal capital.

All four filings lack forward-looking statements, dividends, buybacks, or M&A—companies are in survival mode with no positive catalysts.

Nasdaq delistings (Cambium, Microvast) involve longer cure periods (180 days) vs NYSE American (immediate hearing). Investors should note exchange-specific timelines for trading strategies.

Oral hearing requested Aug 28, 2026—decision expected within 30-60 days. Outcome determines listing status. Watch for auditor TQ International's first report. [Date: Sep-Oct 2026]

180-day cure period ends Feb 2027. Monitor monthly average closing bid price. Any reverse split announcement or contract win could trigger price recovery. [Date: Feb 2027]

Shares expected to quote on OTC Expert Market. Watch for any Nasdaq board review under Rule 5825 (unlikely but possible). [Date: Sep 2026]

Next quarterly filing will show if reverse split stabilized financials. Watch for revenue growth or cash burn updates. [Date: Nov 2026]

Monitor for additional 8-K filings from other micro-caps with auditor resignations or bid price deficiencies—could signal broader wave. [Date: Ongoing]

Any rate cut in H2 2026 could improve micro-cap liquidity and reduce delisting risk. Watch FOMC meetings. [Date: Sep-Dec 2026]

Track SEC Form 4 filings for these companies—any insider buying would be a strong contrarian signal. [Date: Ongoing]